180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released an update on several key initiatives, including announcing the acquisition of an advanced Gaming Technology Platform, positive progress on its Legacy CBD formulation and a strengthened balance sheet. According to the update, the company is shifting its focus as it enters the global iGaming market through its acquisition of a comprehensive intellectual property package, consisting of a complete back-end technology solution for online casino operations. In addition, the company anticipates retaining its current portfolio of biotechnology intellectual property as it reports positive study results exhibiting faster absorption and improved bioavailability for its new CBD pill formulation. 180 also noted that it expects to meet NASDAQ’s continued listing requirement, which requires maintenance of stockholders’ equity of at least $2.5 million; the company is also enhancing its financial position by settling meaningful legacy liabilities at substantial discounts and resolving certain legacy litigation matters
To view the full press release, visit https://ibn.fm/td3sW
About 180 Life Sciences Corp.
180 Life Sciencesis a publicly traded company that focuses on developing new technologies across multiple sectors. With its current portfolio of inflammation-focused intellectual property and its recent acquisition of the Gaming Technology Platform, the company believes it is positioned for growth in both the biotech and iGaming industries. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
